Bio-Path Holdings, Inc.
(NASDAQ : BPTH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.00%88.461.3%$921.65m
AMGNAmgen Inc.
0.02%191.281.2%$567.36m
ONCESpark Therapeutics, Inc.
0.18%113.7911.2%$468.71m
GILDGilead Sciences, Inc.
-0.70%65.170.9%$447.70m
BIIBBiogen Inc.
-1.28%325.641.3%$355.85m
BPTHBio-Path Holdings, Inc.
-5.38%27.82190.1%$311.93m
REGNRegeneron Pharmaceuticals, Inc.
-1.28%409.182.6%$285.34m
ILMNIllumina, Inc.
-1.41%305.483.5%$272.29m
VRTXVertex Pharmaceuticals Incorporated
-0.19%187.741.9%$243.78m
SRPTSarepta Therapeutics, Inc.
0.06%128.4415.4%$216.62m
EXASExact Sciences Corporation
-3.77%91.6125.3%$192.26m
ALXNAlexion Pharmaceuticals, Inc.
-1.04%134.672.0%$180.65m
AAgilent Technologies, Inc.
-0.56%80.651.6%$154.82m
IONSIonis Pharmaceuticals, Inc.
0.15%78.668.3%$100.09m
BMRNBioMarin Pharmaceutical Inc.
-0.58%93.994.3%$100.08m

Company Profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.